-
The Indianapolis-based pharmaceutical company, Eli Lilly and Company, announced Wednesday it will lower the prices of its branded insulin by 70 percent and will introduce more price caps for its non-branded insulin.
-
The Inflation Reduction Act gives Medicare historic new powers to lower prescription drug prices, but lawsuits, loopholes and opposition from the drug industry could undermine them.
-
The price of insulin has more than tripled in the past two decades; A one-month supply of Eli Lilly’s Humalog has jumped from $21 in 1996 to about $275 in 2019.
-
Drugmakers, hospitals, clinics and policymakers have argued for years over a program known as 340B.
-
Older Hoosiers – those age 50 and up – remain one of the most consistent and powerful voting blocs in the state. AARP Indiana talked about what’s at the forefront of their minds heading into this year’s elections.
-
Senator Winnie Brinks says she wants the state to create a Prescription Drug Affordability Board.
-
Indianapolis-based Eli Lilly is joining other pharmaceutical companies in arguing against legislation that aims to reduce drug costs. Congress is debating…
-
Diabetes advocates say Eli Lilly’s latest price reduction on one of its generic insulins is not enough. One group says the cost of insulin is still…
-
Indianapolis-based pharmaceutical company Eli Lilly is reducing the list price of one of its frequently-used insulins for a second time in the last two…
-
Activists rallied against the high cost of prescription drugs, outside of U.S. Sen. Todd Young’s (R-Ind.) Indianapolis office Tuesday. The group wants the…